Gruson, Damien

Fux, Elie

Kemaloğlu Öz, Tuğba

Gouget, Bernard

Lee, Woochang

Shah, Swarup

Liu, Yan

Ebert, Sven

Greaves, Ronda

Bernardini, Sergio

Yang, He Sarina

Figueroa Montes, Luis

2024-09-02

This opinion article highlights the critical role of laboratory medicine and emerging technologies in cardiovascular risk reduction through exposome analysis. The exposome encompasses all external and internal exposures an individual faces throughout their life, influencing the onset and progression of cardiovascular diseases (CVD). Integrating exposome data with genetic information allows for a comprehensive understanding of the multifactorial causes of CVD, facilitating targeted preventive interventions. Laboratory medicine, enhanced by advanced technologies such as metabolomics and artificial intelligence (AI), plays a pivotal role in identifying and mitigating these exposures. Metabolomics provides detailed insights into metabolic changes triggered by environmental factors, while AI efficiently processes complex datasets to uncover patterns and associations. This integration fosters a proactive approach in public health and personalized medicine, enabling earlier detection and intervention. The article calls for global implementation of exposome technologies to improve population health, emphasizing the need for robust technological platforms and policy-driven initiatives to seamlessly integrate environmental data with clinical diagnostics. By harnessing these innovative technologies, laboratory medicine can significantly contribute to reducing the global burden of cardiovascular diseases through precise and personalized risk mitigation strategies.

Department of Laboratory Medicine, Cliniques Universitaires St-Lux, Brussels, Belgium.

Université Catholique de Louvain, Brussels, Belgium.

70492 Pôle de recherche en Endocrinologie, Diabète et Nutrition, Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires Saint-Luc and Université Catholique de Louvain , Brussels, Belgium.

IFCC Division on Emerging Technologies, Milan, Italy.

IFCC Division on Emerging Technologies, Milan, Italy.

R&D Instrumental Analytics Roche Diagnostics GmbH Penzberg, Penzberg, Germany.

Alice Springs Hospital, Alice Springs, Australia.

School of Medicine, Flinder University, Adelaide, SA, Australia.

IFCC Division on Emerging Technologies, Milan, Italy.

National Committee for the Selection of Reference Laboratories, Ministry of Health, Paris, France.

IFCC Division on Emerging Technologies, Milan, Italy.

Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

IFCC Division on Emerging Technologies, Milan, Italy.

Department of Laboratory Medicine, P. D. Hinduja Hospital and Medical Research Centre, Mumbai, India.

IFCC Division on Emerging Technologies, Milan, Italy.

Medical and Scientific Affairs Mindray Bio-Medical Electronics, Shenzhen, China.

IFCC Division on Emerging Technologies, Milan, Italy.

Core Workflow Research and Early Development, Roche Diagnostics International, Rotkreuz, Switzerland.

IFCC Division on Emerging Technologies, Milan, Italy.

Victorian Clinical Genetics Services Murdoch Children's Research Institute, Parkville, VIC, Australia.

Department of Paediatrics, Melbourne Medical School, University of Melbourne, Parkville, VIC, Australia.

IFCC Division on Emerging Technologies, Milan, Italy.

Department of Experimental Medicine, University Tor Vergata, Rome, Italy.

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.

Suarez Angamos Hospital III, EsSalud, Peruvian Medical Association of Clinical Pathology, Peruvian Medical College, Lima, Peru.

Clin Chem Lab Med . 2024 Sep 2. doi: 10.1515/cclm-2024-0788. Online ahead of print.

1437-4331

0000-0002-8010-1404

0000-0001-7823-8797

https://pubmed.ncbi.nlm.nih.gov/39238286/?otool=iaurydwlib

https://hdl.handle.net/10137/13552

artificial intelligence

cardiovascular disease

environment

epigenetics

exposome

metabolomics

Contribution of laboratory medicine and emerging technologies to cardiovascular risk reduction via exposome analysis: an opinion of the IFCC Division on Emerging Technologies.

Journal Article

Publication